MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015
24/7 Wall St. ran a poll for investors this week on where MannKind shares would go into 2015, and the results were overwhelmingly bullish.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 287The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher
A new report from the analysts at Cowen shows that, on average, biotech stocks gained 84% in the 12 months prior to an FDA approval and lost 24% in the 12 months after the…
Poll: Where Does MannKind Stock Go in 2015 After Afrezza Approval?
ThinkstockMannKind Corp. (NASDAQ: MNKD) has seen its shares surge on news that it has finally won U.S. Food & Drug Administration backing. This FDA approval for Type 1 and 2 diabetes is being hailed…
Vindication for MannKind on FDA Approval
After markets closed last Friday, MannKind announced that the FDA had approved Afrezza, a rapid-acting, inhaled insulin powder that improves glycemic control in adults with diabetes.
Two Health Care Stocks With 50% Upside Under Obamacare
ThinkstockThe rise and fall of health care stocks is often hard to grasp, particularly in a world where the health care laws are creating some large potential winners and losers. Many investors guessed that…
MannKind’s Afrezza Inhaled Insulin Drug Gets FDA Approval
ThinkstockThe U.S. Food and Drug Administration (FDA) late Friday afternoon announced that it has approved Afrezza, a rapid-acting, inhaled insulin power that improves glycemic control in adults with diabetes. The FDA estimates that 25.8…
The Real Attraction to Vertex After Cystic Fibrosis Success
Vertex Pharmaceuticals has reported that two Phase 3 studies of its lumacaftor cystic fibrosis drug in combination with its Kalydeco ivacaftor showed positive results. Shares spikes on the news.
As Antibiotics Stop Working, Five Biotechs Seek Cures
ThinkstockOne of the main concerns physicians have agreed upon in recent years has been the overuse of antibiotics by some health care professionals. Their overuse in some cases has led many of the major…
Will Celgene Trigger Other Biotech Stock Splits?
Celgene has decided to join the stock split game. Even though stock splits change nothing fundamentally, 24/7 Wall St. would like to see several competing biotechs join in on the fun.
The Affordable Care Act Is Working Big for These Six Companies
The UBS team highlights six top stocks that are seeing increased prescription volume since the implementation of parts of the Affordable Care Act.
Why Insmed Could Still Double
Insmed shares screamed higher on Wednesday. The driver was an SEC filing stating the FDA had granted Arikace breakthrough therapy designation.
Medtronic and Covidien Deal Is All About Taxes and Dividends
The $42.9 billion merger between medical device makers Medtronic and Covidien was officially confirmed early Monday morning. The deal is a so-called tax inversion.
U.S. Health Care: Most Expensive, Least Effective
ThinkstockThe U.S. health care system is the most expensive among large developed nations. And it produces the worst results. Medical costs are among the highest portions of Americans’ budgets. But people hardly get what…
The MannKind Lifeline Lights Up
MannKind is just about a month away from the FDA decision on Afrezza as the first inhalable insulin treatment for diabetes. Afrezza almost certainly will become a blockbuster drug if approved.
Orexigen Irony: No VIVUS Bounce
ThinkstockVIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America’s ballooning waistline is reaching a critical level, yet VIVUS did not even manage to close up one penny on…